Adult T-cell leukemia/lymphoma (ATLL)
نویسندگان
چکیده
Pathogenesis of the disease: ATLL is associated with HTLV-1 infection of the tumour clone in 100% of the cases. The interval between HTLV-1 infection and the onset of lymphoma is long (10-40 years) and only <5% of infected people actually develops the disease. HTLV-1 produces a trans-regulatory protein (Tax) inducing interleukin-2 (IL-2) and IL-2 receptor expression and consequent polyclonal CD4 cell growth. This T-cell population is at risk for the development of genetic and cytogenetic changes leading to lymphoma.
منابع مشابه
Specific cutaneous manifestations in adult T cell leukemia/lymphoma
Background and aim: Adult T cell leukemia/lymphoma (ATLL) is an aggresive malignancy which may occur in human T lymphotropic virus1(HTLV1) infected persons. HTLV1 is endemic in Khorasan with prevalence of 2.3% in general population. Since specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied ATLL patients in Mashhad.Mate...
متن کاملAbsence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients
Background: Adult T cell leukemia lymphoma (ATLL) is a rare disease, significantly linked to the infection by the human T-cell lymphotropic virus 1(HTLV-1). ATLL is typically preceded by decades of clinical latency during which infected cells accumulate selectable traits leading to a malignant transformation. Amongst all the HTLV-1 infected carriers only about 3-5% will develop ATLL. Despite th...
متن کاملSynergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro
Objective(s): Adult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoid malignancy with low survival rate and distinct geographical distribution. In search for novel chemotherapeutics against ATLL, we investigated the combinatorial effects of parthenolide, a sesquiterpene lactone with valuable pharmaceutical activities, and arsenic trioxide (ATO) in vitro</em...
متن کاملAltered expression of cell cycle regulators in adult T-cell leukemia/lymphoma patients
Abstract Background: Adult T-cell leukemia/lymphoma (ATLL) is caused by human T-cell lymphotropic virus type-1 (HTLV-1). HTLV-1 oncogenes can induce malignancy through controlled gene expression of cell cycle checkpoints in the host cell. HTLV-I genes play a pivotal role in overriding cell cycle checkpoints and deregulate cellular division. In this study, we aimed to determine and comp...
متن کاملRecent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%-5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly prom...
متن کاملTreatment of T-Cell lymphoma.
T-cell lymphoma composes 25% of lymphoid malignancies in Japan. Peripheral T-cell lymphoma (PTCL) unspecified and adult T-cell leukemia/lymphoma (ATLL) are major subtypes of T-cell lymphoma. The Japan Clinical Oncology Group (JCOG) has conducted 7 clinical trials for aggressive non-Hodgkin's lymphoma (NHL) including T-cell lymphoma. JCOG trials revealed that patients with ATLL had an extremely ...
متن کامل